Context: Johnson & Johnson subsidiary Abiomed has been engaged in litigation with Maquet since 2016 over patents relating to intravascular blood pump technologies. Earlier this month, District Judge F. Dennis Saylor IV of the United States District Court for the District of Massachusetts issued an order confirming that a rare “reverse doctrine of equivalents” (RDOE) defense was available to Abiomed, which does not dispute that its accused Impella product meets the literal terms of the patent claim asserted by Maquet (May 7, 2026 ip fray article).
To Read The Full Story
Continue reading your article with a Membership
Counsel
Maquet was represented by Alston & Bird’s Andrew J. Ligotti, Charlie M. Jonas, Christopher L. McArdle, Kirk T. Bradley, Lauren Nicole Griffin, Matthew Scott Stevens, Neal J. McLaughlin, Nicholas Christopher Marais, Paul J. Tanck, Ravi Shah, and Wade G. Perrin.
Abiomed was represented by Desmarais LLP’s Adam Steinmetz, Amy Wann, Brian D. Matty, Davis Gonsalves, Frederick J. Ding, John Desmarais, Kerri-Ann Limbeek, and Kyle Patrick Curry.